ArticleiScience2026
Pan-cancer differentially methylated regions are promising biomarkers for non-invasive diagnosis in multiple cancers.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA methylation is a well-established biomarker for cancer diagnosis, and most studies have focused on cancer-type-specific markers. However, methylation biomarkers applicable to multiple cancer types remain largely unexplored, posing a challenge for multi-cancer detection. Here, we identified pan-cancer differentially methylated regions (DMRs) by analyzing 197 whole-genome bisulfite sequencing datasets spanning 11 malignancies. Compared to cancer-type-specific DMRs, pan-cancer DMRs exhibited conserved methylation alterations across tumor types and significantly greater differential methylation in both tissue and cell-free DNA (cfDNA). A diagnostic model leveraging pan-cancer DMRs accurately detected seven cancer types in a plasma cfDNA dataset (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.